Osimertinib versus comparator first-generation epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in patients with advanced EGFR-mutated non-small cell lung cancer: a Chinese, multicenter, real-world cohort study
Dongming Zhang(Heilongjiang Bayi Agricultural University), Mengzhao Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Jianwen Qin(Tianjin Chest Hospital), Minjiang Chen(Chinese Academy of Medical Sciences & Peking Union Medical College), Ye Guo(Army Medical University), Qingxia Li(Hebei General Hospital), Puyuan Xing(Chinese Academy of Medical Sciences & Peking Union Medical College), Hatim Husain(University of California, San Diego), Antônio Rossi(Università Campus Bio-Medico), Dahai Zhao(Anhui Medical University), Yuequan Shi(Chinese Academy of Medical Sciences & Peking Union Medical College), Yan Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Yangchun Gu(Peking University), Hiroyuki Adachi(Shanxi Medical University), Haoran Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Yuan Cheng(Dalian Medical University), Wěi Li(Shougang (China)), Xiaoyan Liu(Capital Medical University), Jia Liu(Chinese Academy of Medical Sciences & Peking Union Medical College), Jun Chen(Fourth People's Hospital of Taiyuan), Yuhui Zhang(Xuzhou Medical College), Xueqin Chen(Jinan University), Yonggang Liu(Wuhan University), Wei Zhong(Chinese Academy of Medical Sciences & Peking Union Medical College), Qingwei Meng(Shandong Agricultural University), Xiaoling Yang(National Institutes of Health), Min He(Inner Mongolia People's Hospital), Shucai Zhang(Northeastern University), Fangfang Shen(Shanxi Medical University), Li Pang(China Medical University), Bo Jin, Yuling Tang(The First Hospital of Changsha), Jing Zhao(University of Electronic Science and Technology of China), Yu Hong Li(Shanxi Medical University), Feng Gao(Xi'an Jiaotong University), Junzhen Gao(Inner Mongolia Medical University), Xinlin Mu(Peking University), Tao Xin(Harbin Medical University), Xiaoxing Gao(Chinese Academy of Medical Sciences & Peking Union Medical College), Francesco Guerrera(Shanxi Medical University)
Cited by 20
Related Papers
Food, nutrition, physical activity, and the prevention of cancer: a global perspective
|Choice Reviews Online|2008|5.4k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
HIF-1α pathway: role, regulation and intervention for cancer therapy
|Acta Pharmaceutica Sinica B|2015|1.9k